Immuneering Co. (NASDAQ:IMRX) Receives $12.80 Average Price Target from Analysts

Immuneering Co. (NASDAQ:IMRX) has been assigned an average recommendation of “Hold” from the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.80.

Several analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a report on Thursday, November 14th. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research report on Wednesday, November 20th.

Institutional Trading of Immuneering

A number of institutional investors have recently modified their holdings of IMRX. Vanguard Group Inc. raised its stake in shares of Immuneering by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after acquiring an additional 129,851 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Immuneering during the second quarter worth $492,000. Renaissance Technologies LLC purchased a new stake in shares of Immuneering during the 2nd quarter valued at $447,000. Acadian Asset Management LLC purchased a new stake in shares of Immuneering during the 2nd quarter valued at $67,000. Finally, HighTower Advisors LLC boosted its position in shares of Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock worth $132,000 after purchasing an additional 9,400 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $1.73 on Friday. Immuneering has a twelve month low of $1.00 and a twelve month high of $8.07. The firm has a market cap of $53.72 million, a PE ratio of -0.88 and a beta of -0.33. The business has a fifty day simple moving average of $2.03 and a two-hundred day simple moving average of $1.69.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.